BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 12851990)

  • 1. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM; Saini R; Tutrone WD
    J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM
    Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
    Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
    J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM; Saini R
    Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].
    Bos WE; Thio HB; Neumann HA; van der Fits L; Prens EP
    Ned Tijdschr Geneeskd; 2006 May; 150(19):1065-70. PubMed ID: 16733982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologicals in the treatment of psoriasis.
    Boker A; Kimball AB; Rolz-Cruz G
    Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of weight on the efficacy of biologic therapy in patients with psoriasis.
    Clark L; Lebwohl M
    J Am Acad Dermatol; 2008 Mar; 58(3):443-6. PubMed ID: 18083274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic therapeutics in the treatment of psoriasis. Part 1: review.
    Langley RG; Gupta AK; Cherman AM; Inniss KA
    J Cutan Med Surg; 2007; 11(3):99-122. PubMed ID: 17511926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept.
    Tutrone WD; Saini R; Weinberg JM
    IDrugs; 2004 Jan; 7(1):45-9. PubMed ID: 14730466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM; Tutrone WD
    Cutis; 2003 Jan; 71(1):41-5. PubMed ID: 12553629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.
    Saini R; Tutrone WD; Weinberg JM
    Curr Pharm Des; 2005; 11(2):273-80. PubMed ID: 15638763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic agents in the treatment of psoriasis.
    Guarneri F; Guarneri C; Guarneri B
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):193-217. PubMed ID: 19075983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological agents in the treatment of psoriasis.
    Tzu J; Krulig E; Cardenas V; Kerdel FA
    G Ital Dermatol Venereol; 2008 Oct; 143(5):315-27. PubMed ID: 18833073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New biologic therapies for psoriatic disease.
    Bohjanen KA; Prawer SE
    Minn Med; 2004 Mar; 87(3):34-6. PubMed ID: 15080292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.
    Katugampola RP; Lewis VJ; Finlay AY
    Br J Dermatol; 2007 May; 156(5):945-50. PubMed ID: 17388922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancements in the treatment of psoriasis: role of biologic agents.
    Rich SJ; Bello-Quintero CE
    J Manag Care Pharm; 2004; 10(4):318-25. PubMed ID: 15298530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
    Anis AH; Bansback N; Sizto S; Gupta SR; Willian MK; Feldman SR
    J Dermatolog Treat; 2011 Apr; 22(2):65-74. PubMed ID: 20443663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring biologics for the treatment of psoriasis.
    Papp KA
    Clin Dermatol; 2008; 26(5):515-21. PubMed ID: 18755370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic therapy in psoriasis: perspectives on associated risks and patient management.
    Papp KA; Dekoven J; Parsons L; Pirzada S; Robern M; Robertson L; Tan JK
    J Cutan Med Surg; 2012; 16(3):153-68. PubMed ID: 22713438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.